Dr. Robert Ang is the CEO of Vor Bio, a clinical-stage cell and genome engineering therapy company. In this episode, Dr. Ang discusses the challenges of treating cancer, particularly acute myeloid leukemia (AML), and the need for new and innovative approaches. The conversation delves into the challenges of navigating clinical trials during the pandemic and securing funding for research and development. Lastly, he explains how Vor Bio is using cell and gene therapies, such as CAR-T cells and genome engineering, to target AML and potentially cure patients.

Host: John Joson Ng
Editors: Jessie Wong, John Joson Ng
The show notes and transcripts for the episode can be found on
nucleatesingapore.substack.com. For feedback or recommendations on who we should talk to next, please reach out to Joson Ng via johnjoson.n@nucleate.org.

01:15 - Introduction
07:47 - Cancer and treatment modalities
12:02 - Vor’s approach to treating AML
31:55 - Investing in clinical manufacturing
34:21 - Navigating clinical trials and funding during the pandemic
39:53 - Looking ahead